ImageneBio (IMA) Other Non-Current Liabilities (2023 - 2025)

ImageneBio (IMA) posted Other Non-Current Liabilities of $870000.0 for Q4 2025, down 21.48% sequentially from $1.1 million in Q3 2025.

ImageneBio (IMA) Other Non-Current Liabilities (2023 - 2025) Analysis & Trends

ImageneBio has reported Other Non-Current Liabilities for 3 years, with the latest figure at $870000.0 in Q4 2025.

Quarterly Other Non-Current Liabilities changed N/A year-over-year to $870000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $870000.0 (changed N/A YoY) and the FY2025 annual result came in at $870000.0, changed N/A from the prior year.
Other Non-Current Liabilities eased to $870000.0 in Q4 2025 per IMA's latest filing, from $1.1 million in the prior quarter.
Over five years, Other Non-Current Liabilities peaked at $1.1 million in Q3 2025 and troughed at $870000.0 in Q4 2025.
A 3-year average of $1.0 million and a median of $1.0 million in 2024 frame the typical range for Other Non-Current Liabilities.
The widest YoY moves for Other Non-Current Liabilities: up 11.72% in 2025, down 5.71% in 2025.
Over 3 years, Other Non-Current Liabilities stood at $950000.0 in 2023, then climbed by 10.0% to $1.0 million in 2024, then fell by 16.75% to $870000.0 in 2025.
According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $870000.0, $1.1 million, and $1.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.50 Bn	131.65 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.10 Bn	78.10 Bn	3.93 Bn
3	Argenx Se	65.59 Bn	60.41 Bn	1.37 Bn
4	Moderna	56.75 Bn	51.62 Bn	52.00 Mn
5	BeOne Medicines	42.11 Bn	37.01 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.64 Bn	28.33 Bn	992.69 Mn
7	BioNTech SE	27.80 Bn	9.41 Bn	668.28 Mn
8	Insmed	27.51 Bn	26.35 Bn	358.27 Mn
9	Royalty Pharma	27.29 Bn	26.45 Bn	-
10	ImageneBio	48.35 Mn	-87.00 Mn	-

Download Data